Blueshift Asset Management LLC Invests $546,000 in Hologic, Inc. (NASDAQ:HOLX)

Blueshift Asset Management LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 7,573 shares of the medical equipment provider's stock, valued at approximately $546,000.

Several other large investors also recently made changes to their positions in the stock. iA Global Asset Management Inc. grew its holdings in shares of Hologic by 49.7% during the fourth quarter. iA Global Asset Management Inc. now owns 13,398 shares of the medical equipment provider's stock worth $966,000 after buying an additional 4,448 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Hologic by 82.9% during the 4th quarter. Teacher Retirement System of Texas now owns 649,883 shares of the medical equipment provider's stock worth $46,850,000 after acquiring an additional 294,538 shares during the last quarter. Royal London Asset Management Ltd. grew its stake in shares of Hologic by 2.8% during the 4th quarter. Royal London Asset Management Ltd. now owns 344,465 shares of the medical equipment provider's stock worth $24,832,000 after acquiring an additional 9,454 shares in the last quarter. Xponance Inc. raised its holdings in shares of Hologic by 3.3% in the fourth quarter. Xponance Inc. now owns 34,027 shares of the medical equipment provider's stock valued at $2,453,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Boston Partners lifted its position in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price for the company. Citigroup lowered their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. BNP Paribas upgraded Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Evercore ISI cut their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Stock Performance

HOLX stock traded down $1.09 during mid-day trading on Tuesday, hitting $60.80. 2,378,048 shares of the company were exchanged, compared to its average volume of 1,754,307. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The business has a 50 day simple moving average of $65.89 and a 200-day simple moving average of $73.81. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.